



For Immediate Release

**DiFUSION Technologies' New Interbody Implants
Are Made of Solvay's Zeniva® PEEK**

*Versatile Biomaterial Brings Exceptional
Performance in Spinal Devices*

ALPHARETTA, Ga., April 11, 2011 – DiFUSION Technologies Inc., based in Austin, Texas, a supplier of minimally invasive spinal implants, recently received 510(k) clearance from the U.S. Food & Drug Administration (FDA) for its new Xiphos™ line of posterior interbody devices made of Zeniva® polyetheretherketone (PEEK) resin from Solvay Advanced Polymers, LLC. Zeniva PEEK – part of Solvay's line of Solviva® Biomaterials – has a modulus very close to that of bone plus excellent toughness and fatigue resistance. The FDA clearance was based in part on Solvay's well-developed master access file for Zeniva PEEK.

The interbody implants, made from Zeniva PEEK rod, are for intervertebral body fusion of the thoracolumbar spine and are intended for use with supplemental internal fixation. These implants are hollow so that bone can grow through the device, fusing the adjacent bony surfaces of the vertebrae.

The Xiphos posterior interbody platform includes a range of implant shapes and sizes for varying patient anatomy and surgical preference and allows for posterior, posterior oblique, and transforaminal approaches. These best-in-class implants are expected to serve as a platform for future development.

“We have found Zeniva PEEK to be markedly stronger than comparable competitive materials based on our biomechanical testing, offering the exceptional properties that are required in this critical application,” said Derrick Johns, managing director and CEO of DiFUSION Technologies. The company plans to use Zeniva PEEK for future non-antimicrobial products.

Zeniva PEEK offers numerous advantages over metals such as titanium for these intervertebral implantable devices. The material offers many important benefits including biocompatibility, chemical inertness, and a modulus of elasticity that is closer to that of bone than traditionally used metals. Based on biocompatibility testing, Zeniva PEEK demonstrates no evidence of cytotoxicity, sensitization, irritation, or acute systemic toxicity. It also boasts high strength and stiffness and has radiolucent properties which permit x-ray procedures.

“With over 10 devices now cleared through the FDA via the 510(k) process, including six in spinal implants, we are excited about the growing acceptance of this material both in the market and the FDA,” said Shawn Shorrock, global healthcare market manager for Solvay Advanced Polymers. “We’ve made significant investments and have performed all applicable required testing to ensure that our Zeniva PEEK meets or exceeds the critical regulatory performance standards set by the FDA.”

Zeniva PEEK and the entire line of Solviva[®] Biomaterials are manufactured in compliance with the relevant aspects of ISO 13485 and under the relevant aspects of current Good Manufacturing Practices. Solvay’s biomaterial manufacturing processes are carefully validated and enhanced controls provide product traceability. In addition, all materials are tested in an accredited lab that is ISO 17025 compliant.

Solvay is currently in active product trials with several medical device manufacturers using Zeniva PEEK as well as other Solviva biomaterials.

In addition to Zeniva PEEK, Solvay's line of Solviva Biomaterials includes Proniva[®] self-reinforced polyphenylene (SRP), one of the world's stiffest and strongest unreinforced thermoplastics that offers exceptional hardness and biocompatibility; Veriva[®] polyphenylsulfone (PPSU), which provides unsurpassed toughness combined with transparency and excellent biocompatibility; and Eviva[®] polysulfone (PSU), which offers practical toughness in a strong, transparent polymer. These sterilizable products are available in injection molding and extrusion grades as well as stock shapes for machined components.

About DiFUSION Technologies

Founded in 2008 in Austin, Texas, DiFUSION Technologies Inc. is a medical device company focused on reducing the rising incidence of surgical site infections in orthopedic and spine surgery through the development of a suite of patented antimicrobial orthobiologic polymeric implants. Initially focused on the multi-billion-dollar spinal implant market, the company has developed a technology with applicability across a variety of orthopedic segments using well characterized implants with benefits for the patient, surgeon, and payer. For more information, call (512) 716-8928 or visit www.difusiontech.com.

About Solvay Advanced Polymers

Solvay Advanced Polymers, LLC, produces more products with more performance than any other polymer company in the world. This gives design engineers worldwide more ways to solve top design challenges in automotive, medical, electronics, aerospace and other demanding industries. Learn more at www.solvayadvancedpolymers.com.

Solvay is an international industrial Group active in Chemistry. It offers a broad range of products and solutions that contribute to improving quality of life. The Group is headquartered in Brussels and its companies employ 17,000 people in over 40 countries. In 2010, its consolidated sales amounted to EUR 7.1 billion. Solvay is listed on the NYSE Euronext stock exchange in Brussels (NYSE Euronext: [SOLB.BE](http://www.nyse.com/quote/NYSE:SOLB.BE) - Bloomberg: [SOLB.BB](http://www.bloomberg.com/quote/SOLB:BB) - Reuters: [SOLBt.BR](http://www.reuters.com/quote/SOLBt.BR)). Details are available at www.solvay.com.

###

Press Contact:

Joseph Grande

413.684.2463

solvayap.press@solvay.com

